Recent developments in CCR2 antagonists

被引：155

作者：

Xia, Mingde ^{[1
]}

Sui, Zhihua ^{[1
]}

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev LLC, Cranbury, NJ 08512 USA

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2009年 / 19卷 / 03期

关键词：

asthma; CCR2; antagonist; MCP-1; multiple sclerosis; rheumatoid arthritis; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CHEMOKINE RECEPTOR-2 ANTAGONISTS; DISEASE; DISCOVERY; RECRUITMENT; MACROPHAGES;

D O I：

10.1517/13543770902755129

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Monocyte chemoattractant protein-1 (MCP-1) is a major chemoattractant for monocytes and memory T cells by means of their binding to its specific cell-surface receptor, CC-chemokine receptor-2 (CCR2). CCR2 belongs to the G-protein-coupled seven-transmembrane receptor superfamily. The evidence in favor of CCR2 and MCP-1 having dominant roles in monocyte chemotaxis and chronic inflammation was provided by CCR2 and MCP-1 knockout mice. It has been recognized that CCR2 antagonists are potential therapeutic agents in preventing, treating, or ameliorating a CCR2-mediated inflammatory syndrome or disease such as psoriasis, uveitis, rheumatoid arthritis, multiple sclerosis, asthma, obesity, and chronic obstructive pulmonary disease. This review summarizes recent developments in small-molecule CCR2 antagonists disclosed by patent applications published between 2005 and 2008 and related publications.

引用

页码：295 / 303

页数：9

共 42 条

[11]

Cai D., 2005, WO Patent, Patent No. [WO2005044795, 2005044795, 2005044795 A1]

[12] Capped diaminopropionamide-glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2) [J].

Carter, Percy H. ;

Brown, Gregory D. ;

Friedrich, Sarah R. ;

Cherney, Robert J. ;

Tebben, Andrew J. ;

Lo, Yvonne C. ;

Yang, Gengjie ;

Jezak, Heather ;

Solomon, Kimberly A. ;

Scherle, Peggy A. ;

Decicco, Carl P. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (19) :5455-5461

[13] Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts - Evidence for autocrine regulation of myofibroblast differentiation [J].

Carulli, MT ;

Ong, VH ;

Ponticos, M ;

Xu, SW ;

Abraham, DJ ;

Black, CM ;

Denton, CP .

ARTHRITIS AND RHEUMATISM, 2005, 52 (12) :3772-3782

[14] Chemokines in the pathogenesis of vascular disease [J].

Charo, IF ;

Taubman, MB .

CIRCULATION RESEARCH, 2004, 95 (09) :858-866

[15]

Charvat T. T., 2008, PCT Int. Appl., Patent No. [WO 2008/008375, 2008008375]

[16] Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists [J].

Cherney, Robert J. ;

Mo, Ruowei ;

Meyer, Dayton T. ;

Nelson, David J. ;

Lo, Yvonne C. ;

Yang, Gengjie ;

Scherle, Peggy A. ;

Mandlekar, Sandhya ;

Wasserman, Zelda R. ;

Jezak, Heather ;

Solomon, Kimberly A. ;

Tebben, Andrew J. ;

Carter, Percy H. ;

Decicco, Carl P. .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (04) :721-724

[17] Leishmania-derived murine monocyte chemoattractant protein 1 enhances the recruitment of a restrictive population of CC chemokine receptor 2-positive macrophages [J].

Conrad, Sean M. ;

Strauss-Ayali, Dalit ;

Field, Ann E. ;

Mack, Matthias ;

Mosser, David M. .

INFECTION AND IMMUNITY, 2007, 75 (02) :653-665

[18]

Dawson J, 2003, EXPERT OPIN THER TAR, V7, P35

[19]

EPIX, 2008, Patent No. 2008045564

[20]

EPIX, 2008, Patent No. 2008045558

← 1 2 3 4 5 →